Page last updated: 2024-12-06

picoprazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Picoprazole is a proton pump inhibitor (PPI) that is used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. It is a substituted benzimidazole derivative that irreversibly inhibits the hydrogen potassium adenosine triphosphatase (H+/K+ ATPase) enzyme, which is responsible for pumping hydrogen ions into the stomach. This inhibition reduces gastric acid production, which helps to relieve symptoms of GERD and other conditions. Picoprazole is generally well-tolerated, but it can cause side effects such as headache, diarrhea, and abdominal pain. It is important to note that PPIs, including picoprazole, are associated with an increased risk of bone fractures, particularly in older adults. Picoprazole is synthesized through a multi-step process involving the reaction of a benzimidazole derivative with a substituted pyridine. The final product is a white, crystalline powder that is soluble in organic solvents. Picoprazole is currently undergoing research for its potential use in the treatment of other conditions, such as Barrett's esophagus and Helicobacter pylori infection. The compound is studied due to its potent anti-secretory activity and its ability to suppress gastric acid production. The research aims to investigate the safety and efficacy of picoprazole in treating various diseases and to explore its potential therapeutic applications.'

picoprazole: inhibits gastric acid secretion by blocking (H+ + K+)ATPase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71223
CHEMBL ID2106940
SCHEMBL ID994783
MeSH IDM0092579

Synonyms (26)

Synonym
picoprazole
h-149/94
D05901
78090-11-6
picoprazole (inn)
methyl 6-methyl-2-[(3-methylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole-5-carboxylate
picoprazolum
picoprazolum [inn-latin]
unii-s882yc38oj
methyl 6-methyl-2-(((3-methyl-2-pyridyl)methyl)sulfinyl)-5-benzimidazolecarboxylate
picoprazol [inn-spanish]
picoprazol
s882yc38oj ,
1h-benzimidazole-5-carboxylic acid, 6-methyl-2-(((3-methyl-2-pyridinyl)methyl)sulfinyl)-, methyl ester
picoprazole [inn]
CHEMBL2106940
1h-benzimidazole-6-carboxylicacid, 5-methyl-2-[[(3-methyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester
5-methyl-2-[[(3-methyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole-6-carboxylic acid methyl ester
SCHEMBL994783
CS-6632
HY-15384
FT-0758525
Q27289045
DTXSID80868463
methyl 6-methyl-2-[(3-methylpyridin-2-yl)methanesulfinyl]-1h-benzimidazole-5-carboxylate
AKOS040734788

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Measurement of the plasma concentration of unchanged omeprazole revealed an intraduodenal bioavailability of approximately 70% whereas the oral bioavailability was only approximately 15%."( Inhibition of gastric acid secretion by omeprazole in the dog and rat.
Carlsson, E; Junggren, U; Larsson, H; Olbe, L; Sjöstrand, SE; Skånberg, I; Sundell, G, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (91.67)18.7374
1990's1 (8.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 123.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index123.92 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index224.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (123.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]